Essa Pharma INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
EPIX
Essa Pharma INCTang Capital Management and its affiliated entities have filed an amended Schedule 13G, reporting zero beneficial ownership of ESSA Pharma Inc. common shares.
EPIX
Essa Pharma INCTang Capital Management and its affiliated entities have filed an amended Schedule 13G, reporting zero beneficial ownership of ESSA Pharma Inc. common shares.
EPIX
Essa Pharma INCMorgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have reported reducing their beneficial ownership in ESSA Pharma Inc. to below the 5% threshold.
EPIX
Essa Pharma INCTang Capital Management and affiliated entities have amended their SEC filing for ESSA Pharma Inc., indicating a shift from an active to a passive investment strategy, no longer seeking to influence company control.
EPIX
Essa Pharma INCPFM Health Sciences and its affiliates have reported that they no longer beneficially own any common shares of ESSA Pharma Inc., holding 0% of the outstanding class as of December 31, 2024.
EPIX
Essa Pharma INCSCHEDULE 13G/A: BML Investment Partners Corrects Significant Stake in ESSA Pharma, Disclosing 9.5% Ownership
BML Investment Partners, L.P. has filed an amended Schedule 13G to correct its beneficial ownership in ESSA Pharma Inc., reporting a 9.5% stake as of December 31, 2024.
EPIX
Essa Pharma INCBML Investment Partners, L.P. has filed an amended Schedule 13G, reporting a 9.4% passive beneficial ownership stake in ESSA Pharma Inc. as of December 31, 2024.
EPIX
Essa Pharma INCRTW Investments, LP and its Managing Partner, Dr. Roderick Wong, have jointly disclosed a beneficial ownership of 2.5% of ESSA Pharma Inc.'s common shares as of December 31, 2024.
EPIX
Essa Pharma INCSoleus Capital Master Fund, L.P. and related entities have filed an amended Schedule 13G/A, reporting a passive beneficial ownership of 5.1% in Essa Pharma, Inc.'s common stock as of December 31, 2024.